Connect Biopharma Holdings Limited (CNTB)
- Previous Close
1.4500 - Open
1.4300 - Bid --
- Ask --
- Day's Range
1.4016 - 1.4793 - 52 Week Range
0.5350 - 2.8400 - Volume
11,936 - Avg. Volume
162,490 - Market Cap (intraday)
79.073M - Beta (5Y Monthly) -0.49
- PE Ratio (TTM)
-- - EPS (TTM)
-1.0800 - Earnings Date Apr 16, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.12
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.
www.connectbiopharm.comRecent News: CNTB
Performance Overview: CNTB
Trailing total returns as of 5/9/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CNTB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CNTB
Valuation Measures
Market Cap
79.90M
Enterprise Value
-38.29M
Trailing P/E
--
Forward P/E
0.89
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.79
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.66
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-27.07%
Return on Equity (ttm)
-46.03%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-59.5M
Diluted EPS (ttm)
-1.0800
Balance Sheet and Cash Flow
Total Cash (mrq)
118.7M
Total Debt/Equity (mrq)
0.46%
Levered Free Cash Flow (ttm)
-27.07M
Research Analysis: CNTB
Company Insights: CNTB
CNTB does not have Company Insights